Skip to main content
. 2020 Jul 2;55(1):118–128. doi: 10.1007/s43441-020-00196-2

Figure 4.

Figure 4.

Submitting a Certificate of Pharmaceutical Product (CPP) at the Time of a New Active Substance (NAS) Marketing Authorization Application (MAA) or Afterward: the Effect on NAS Rollout in Emerging Markets.